Never miss out on the latest news!
Sign up to the Thrombosis Adviser newsletter.
This section examines the current use of antiplatelet therapy/ASA for stroke prevention in patients with AF, and discusses the most recent guideline recommendations
The use of antiplatelet therapy (including ASA, aspirin) for stroke prevention in AF is increasingly limited:
Recent guidelines have highlighted the limited risk–benefit of antiplatelet therapy for stroke prevention based on the efficacy profile and potential for causing serious bleeding events:
Antiplatelet agents used for stroke prophylaxis in patients with atrial fibrillation
|Drug||Target||Dose/regimen||Supporting study/ substudies|
|ASA||Irreversibly inhibits the COX-1 enzyme||75–325 mg once daily||ACTIVE-W1 ACTIVE-A2 Meta-analysis3|
|Clopidogrel||Thienopyridine – irreversibly binds to the adenosine diphosphate receptor P2Y7||75 mg once daily, administered in combination with ASA 75–100 mg daily|